Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Journal of Pathology, Wiley, Vol. 244, No. 2 ( 2018-02), p. 176-188
    Abstract: Mechanisms underlying functional recovery after stroke are little known, and effective drug intervention during the delayed stage is desirable. One potential drug target, the protein–protein interaction between neuronal nitric oxide synthase (nNOS) and postsynaptic density protein 95 (PSD‐95), is critical to acute ischaemic damage and neurogenesis. We show that nNOS–PSD‐95 dissociation induced by microinjection of a recombinant fusion protein, Tat‐nNOS‐N 1–133 , or systemic administration of a small‐molecule, ZL006, from day 4 to day 10 after photothrombotic ischaemia in mice reduced excessive tonic inhibition in the peri‐infarct cortex and ameliorated motor functional outcome. We also demonstrated improved neuroplasticity including increased dendrite spine density and synaptogenesis after reducing excessive tonic inhibition by nNOS–PSD‐95 dissociation. Levels of gamma‐aminobutyric acid (GABA) and GABA transporter‐3/4 (GAT‐3/4) are increased in the reactive astrocytes in the peri‐infarct cortex. The GAT‐3/4‐selective antagonist SNAP‐5114 reduced tonic inhibition and promoted function recovery, suggesting that increased tonic inhibition in the peri‐infarct cortex was due to GABA release from reversed GAT‐3/4 in reactive astrocytes. Treatments with Tat‐nNOS‐N 1–133 or ZL006 after ischaemia inhibited astrocyte activation and GABA production, prevented the reversal of GAT‐3/4, and consequently decreased excessive tonic inhibition and ameliorated functional outcome. The underlying molecular mechanisms were associated with epigenetic inhibition of glutamic acid decarboxylase 67 and monoamine oxidase B expression through reduced NO production. The nNOS–PSD‐95 interaction is thus a potential target for functional restoration after stroke and ZL006, a small molecule inhibitor of this interaction, is a promising pharmacological lead compound. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
    Type of Medium: Online Resource
    ISSN: 0022-3417 , 1096-9896
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 1475280-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages